Healthspan Industry
What does a life of maximum vitality look like — and what is the industry that makes it possible?
The global wellness economy reached $5.6 trillion in 2024 and is projected to hit $8.5 trillion by 2027 [Global Wellness Institute 2024]. Against that, global sick-care spend is $10.7 trillion — 80% of it treating conditions that are largely preventable [WHO Global Health Expenditure 2024, CDC 2023]. The structural gap is not a funding gap. It is a model gap: the industry optimised for episodes of disease is the wrong infrastructure for a population that wants decades of vitality.
The Structural Gap
The model being disrupted is sick-care itself. Reactive, episodic, provider-controlled care designed around the question "what's wrong?" is being reoriented by a different question: "how well can I function, and for how long?" The shift is from treating disease after onset to maintaining and extending vitality before onset.
Three forces are converging to make that shift possible at scale:
Wearable sensors are now on 100M+ wrists [Grand View Research 2024], generating continuous biomarker streams — HRV, SpO2, sleep architecture, glucose trends — that the sick-care system never captured. Only 3% of US health spending is preventive despite 70–80% of healthcare costs arising from preventable chronic conditions [Milken Institute 2023]. And longevity research is accelerating: Nature Aging tracked a 3× increase in published longevity interventions between 2019 and 2023.
The platform that converts that sensor stream into trusted, personalised protocols — and sustains compliance across months and years — captures the layer that sick-care never built.
Disruption composite: 22/30 = 0.73. Scored on six canonical dimensions against the healthspan (proactive/consumer) framing — not the clinical sick-care framing. The old sick-care score was 0.57, driven by long B2B sales cycles and regulatory friction. The healthspan framing changes the wedge: consumer segments are app-store fast; the universal JTBD ("live longer, feel better") scores 4/5; AI leverage for protocol personalisation scores 5/5.
Conviction: MEDIUM-HIGH. Disconfirming evidence: 80% of digital health users abandon an app within two weeks [Harvard Business Review 2023]; most people only engage with health reactively; the supplement industry carries a trust deficit from low-evidence claims; habit change at population scale has not been demonstrated at any price point.
The Compliance Wall
The hardest structural problem in healthspan is not biology — it is behaviour. The 80% abandonment rate within two weeks is the industry's defining failure mode [HBR 2023]. It is not a motivation problem; it is a systems design problem. The protocols that succeed are built around existing triggers, minimum effective dose, social reinforcement, and fast-feedback biomarker signals. The platform that solves compliance at scale owns the category — because compliance is the precondition for every other outcome the industry promises.
Friction Map
Each friction below is scored on ABCD technology maturity (AI / Cloud / Blockchain / Devices) and current market status.
Episodic-only care model — maturity: AI + Cloud, status: Wide open. Continuous monitoring converts the visit-based model to a stream-based model. The infrastructure exists; the integration layer does not.
Behaviour change compliance — maturity: AI, status: Not solved. 80% abandonment is the moat for whoever cracks habit formation at scale. No platform has achieved >50% 90-day retention at consumer scale.
Fragmented biomarker data — maturity: Cloud + AI, status: Not solved. Wearables, labs, genomics, and lifestyle signals exist in separate silos. No neutral aggregator has built the unified longitudinal layer with patient-sovereign governance.
Health coaching access gap — maturity: AI, status: Growing. AI coaching below the human coach tier — personalised, 24/7, protocol-driven — is the wedge for the consumer healthspan market.
Nutrition personalisation — maturity: AI + Devices, status: Growing. Continuous glucose monitoring and gut microbiome testing are breaking one-size-fits-all nutrition. The protocol layer that converts individual metabolic data into daily guidance does not yet exist at scale.
Mental fitness access — maturity: AI + Cloud, status: Wide open. Shortest regulatory path, highest unmet demand, lowest evidence threshold for consumer products. Best sub-vertical entry.
Longevity protocol fragmentation — maturity: AI, status: Growing. NAD+ precursors, fasting, cold/heat exposure, peptides — expert-only today. A protocol personalisation layer that grades evidence and adapts by biomarker response is the opportunity.
Sleep optimisation — maturity: Devices + AI, status: Growing. Rich wearable sleep architecture data; proven interventions (CBT-I, light, temperature). The gap: disconnected stack, no unified protocol engine.
Movement / mobility decline — maturity: Devices + AI, status: Growing. 80%+ of adults miss WHO activity guidelines [WHO 2022]. AI-coached movement programs are proven effective; unscaled.
Sick-care data lock-in — maturity: Blockchain, status: Wide open. Patient biomarker and health history data trapped in EHR systems (Epic, Oracle Health/Cerner). Cannot follow the patient into the preventive layer without patient-sovereign governance.
Sub-Verticals by Entry Attractiveness
The wedge is not uniform. The best entry combines low regulatory burden with strong data moat potential.
Behavioral / mental health — low regulatory burden, consumer-paid, massive unmet demand. Best wedge. Data moat builds from longitudinal outcome data across coaching and therapy programs.
Sleep optimisation — wearable data already rich, proven interventions exist. Medium regulatory burden. Data moat: multi-year sleep architecture.
Movement / fitness coaching — large existing market ($96B global gym revenue [IHRSA 2024]); AI coaching is the disruption layer. Low regulatory burden. Risk: crowded and price-sensitive.
Nutrition personalisation — CGM and microbiome testing are the wedge. Medium regulatory burden. Data moat: individual metabolic response profiles.
Longevity protocols — highest growth, lowest evidence standardisation. Diagnostics and supplements: low regulatory burden. Pharmaceutical longevity (rapamycin, senolytics): high regulatory burden. Best entry: personalised diagnostics that guide the protocol stack.
Value-based care adjacency — outcome-attributable prevention programs that insurers pay for. Highest regulatory burden but highest willingness to pay. Requires clinical evidence base before entry.
DeSci and Data Sovereignty
The research coordination problem and the data governance problem converge in the same place: who owns the longitudinal health record, and who funds the research that doesn't have a reimbursement path?
DeSci protocols — AthenaDAO (women's health), VitaDAO (longevity), LabDAO (research infrastructure) — demonstrate the model: patient-contributed data with cryptographic consent, research outputs published to the commons, funding coordination via token governance. This is the alternative to centralised pharma for the disease areas and research questions that the reimbursement system ignores.
ZK proofs and smart contract consent are the technical layer: data shared without exposing personal health information, consent specific and revocable, enforced by the protocol rather than an administrator.
Marketplace
Pearl Health ($2.5B) — value-based care outcome pricing for primary care. Owns the outcome measurement layer. Proved the VBC wedge.
InsideTracker — biomarker optimisation from blood panels and wearables. Consumer-paid, no insurance cycle. Clearest existing example of the healthspan model.
Forward Health CarePods — AI-first primary care hardware + software. Removes the human bottleneck for routine visits. Membership-priced.
Whoop / Oura Ring — subscription wearables with rich longitudinal recovery and sleep data. The data moat exists; the protocol intelligence layer is shallow. Acquisition targets for any full-stack entrant.
AthenaDAO — DeSci community funding for women's health research. Token-aligned incentives fund research pharma ignores.
The Runway That Creates the Next Industry
Healthspan is the biological foundations layer — the vitality runway. The longer it extends, the more years people have to fill. When AI compresses knowledge work and extended vitality compresses the sick years, the decades that remain need meaning, character, and belonging — the layer above Foundations. That is a different industry. Healthspan's job is to maximise the runway; what people do with it is the adjacent opportunity.
Signals
A healthspan market is maturing when consumer health spending shifts from episodic (visit, treat, discharge) to subscription (monitor, protocol, iterate). Watch for: wearable adoption exceeding 30% of target demographic; AI health coaching retention crossing 50% at 90 days; outcome-attributed prevention programs entering employer benefits packages; patient-sovereign data governance standards adopted by a major EHR vendor.
A healthspan platform is working when biomarker trends improve within 8 weeks of protocol start and retention holds at 90 days. It is failing when data collection frequency drops — the leading indicator of churn 60 days later.
Context
- Principles — Data, nomenclature, value creation
- Performance — Friction map and disruption scoring
- Platform — Technology infrastructure and VSaaS landscape
- Protocols — Behaviour-change protocols and longevity practice
- Players — Who competes for the longitudinal health relationship
- Tight Five — The 5P framework applied across industries
- Medical Science — The research frontier
- DePIN — Sensor networks for continuous patient monitoring
- Agency — The human development layer above the healthspan runway
Questions
If healthspan has the highest AI leverage of any industry, why does the compliance wall still hold — and what is the intervention design that breaks it?
- If the moat is longitudinal data exclusivity, what is the minimum continuous record length before a competitor cannot replicate it quickly?
- When sick-care data lock-in (EHR) breaks via FHIR mandates and DeSci protocols, does patient-sovereign health data shift the power balance from provider to person?
- Which sub-vertical has the shortest regulatory path AND the deepest data moat — and is that combination possible in the same product?